Company intelligence / Profile preview

Fluart Innovative Vaccines

Pilisborosjenő, Pest, Hungaryfluart.hu ↗
Ownership
Private
Employees
~50
Development stage
Other
01

Overview

Fluart has completed multiple clinical trials for its seasonal trivalent/quadrivalent influenza vaccines in both adults and children, demonstrating immunogenicity and safety consistent with regulatory requirements for such products. Its lead products have reached late-stage development or post-marketing studies within Hungary.

Therapeutic areas
Infectious Diseases
Modalities
VaccineBiologicBacteriophage
Industry
Biotech
02

Drug pipeline

9 assets

Fluval AB vaccine

4

8 more assets in the full pipeline.

Beyond the preview

Go deeper on Fluart Innovative Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fluart Innovative Vaccines.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call